Business
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":" BAUDETTE, Minn.--(BUSINESS WIRE)--\nANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open.\n\nNikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:\n\n\n\nDate\n\n\n\n\nThursday, March 9, 2023\n\n\n\n\n\nTime\n\n\n\n\n8:30 a.m. ET\n\n\n\n\n\nToll free (U.S.)\n\n\n\n\n800-343-5172\n\n\n\n\n\nWebcast (live and replay)\n\n\n\n\nwww.anipharmaceuticals.com, under the “Investors” section\n\n\n\n\nA replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-934-8367 and entering access code 2895031.\n\nAbout ANI\n\nANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230222005924/en/\n\nInvestor Relations:\nLisa M. Wilson, In-Site Communications, Inc.\n212-452-2793\[email protected]\n\nSource: ANI Pharmaceuticals, Inc.","length":4768,"tagName":"div"}]